CN112236413A - 结晶曲尼司特盐及其药物用途 - Google Patents

结晶曲尼司特盐及其药物用途 Download PDF

Info

Publication number
CN112236413A
CN112236413A CN201980033248.9A CN201980033248A CN112236413A CN 112236413 A CN112236413 A CN 112236413A CN 201980033248 A CN201980033248 A CN 201980033248A CN 112236413 A CN112236413 A CN 112236413A
Authority
CN
China
Prior art keywords
tranilast
crystalline
salt
peaks
infrared spectrum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980033248.9A
Other languages
English (en)
Chinese (zh)
Inventor
J·霍兰
C·弗兰姆普敦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novomix Technology Co ltd
Original Assignee
Novomix Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novomix Technology Co ltd filed Critical Novomix Technology Co ltd
Publication of CN112236413A publication Critical patent/CN112236413A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/68—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom and to a carbon atom of a six-membered aromatic ring wherein at least one ortho-hydrogen atom has been replaced
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/38—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201980033248.9A 2018-08-14 2019-08-14 结晶曲尼司特盐及其药物用途 Pending CN112236413A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862718563P 2018-08-14 2018-08-14
US62/718,563 2018-08-14
PCT/EP2019/071881 WO2020035546A1 (en) 2018-08-14 2019-08-14 Crystalline tranilast salts and their pharmaceutical use

Publications (1)

Publication Number Publication Date
CN112236413A true CN112236413A (zh) 2021-01-15

Family

ID=67997566

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980033248.9A Pending CN112236413A (zh) 2018-08-14 2019-08-14 结晶曲尼司特盐及其药物用途

Country Status (5)

Country Link
US (2) US11078155B2 (cg-RX-API-DMAC7.html)
EP (1) EP3837238B1 (cg-RX-API-DMAC7.html)
JP (1) JP7372259B2 (cg-RX-API-DMAC7.html)
CN (1) CN112236413A (cg-RX-API-DMAC7.html)
WO (1) WO2020035546A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11078155B2 (en) * 2018-08-14 2021-08-03 Nuformix Technologies Limited Crystalline tranilast salts and their pharmaceutical use
US20230146308A1 (en) * 2020-03-19 2023-05-11 Softhale Nv Method for the treatment nlrp3-associated diseases
AU2022443590A1 (en) 2022-02-28 2024-10-17 Nuformix Technologies Limited Compositions and methods for treatment of idiopathic pulmonary fibrosis

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4587356A (en) * 1981-09-01 1986-05-06 Kissei Pharmaceutical Co., Ltd. Process for the production of nuclear substituted cinnamoylanthranilic acid derivatives
ES8606846A1 (es) * 1985-07-11 1986-05-16 Uriach & Cia Sa J Procedimiento de obtencion del acido 2-((3-3,4-dimetoxifenil-1-oxo-2-propenil)amino)benzoico
EP0189861A2 (en) * 1985-01-26 1986-08-06 Showa Denko Kabushiki Kaisha Percutaneous absorption accelerator for ionic water-soluble medicine
US5356620A (en) * 1989-04-04 1994-10-18 Kissei Pharmaceutical Co. Ltd. Pharmaceutical compositions containing N-(3,4-dimethoxycinnamoyl) anthranilic acid
JP2001187728A (ja) * 1999-12-28 2001-07-10 Lion Corp 眼科用組成物
JP2005247819A (ja) * 2003-09-30 2005-09-15 Rohto Pharmaceut Co Ltd 透明包装体入りトラニラスト含有医薬製剤
JP2006306765A (ja) * 2005-04-27 2006-11-09 Nippon Tenganyaku Kenkyusho:Kk トラニラスト水性点眼液
WO2010071865A1 (en) * 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
CN104379130A (zh) * 2012-03-30 2015-02-25 诺弗米克斯有限公司 曲尼司特组合物和共结晶体
KR20180078966A (ko) * 2016-12-30 2018-07-10 한국과학기술원 진동 감쇠 장치

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5848545B2 (ja) * 1974-04-18 1983-10-28 キツセイヤクヒンコウギヨウ カブシキガイシヤ シンキホウコウゾクカルボンサンアミドユウドウタイ ノ セイゾウホウホウ
IL150524A0 (en) 2000-01-07 2003-02-12 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
JPWO2007046544A1 (ja) 2005-10-21 2009-04-30 株式会社 メドレックス カルボキシル基を有する肥満細胞脱顆粒抑制剤と有機アミンとの塩を含有する外用剤
US11078155B2 (en) * 2018-08-14 2021-08-03 Nuformix Technologies Limited Crystalline tranilast salts and their pharmaceutical use

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4587356A (en) * 1981-09-01 1986-05-06 Kissei Pharmaceutical Co., Ltd. Process for the production of nuclear substituted cinnamoylanthranilic acid derivatives
EP0189861A2 (en) * 1985-01-26 1986-08-06 Showa Denko Kabushiki Kaisha Percutaneous absorption accelerator for ionic water-soluble medicine
ES8606846A1 (es) * 1985-07-11 1986-05-16 Uriach & Cia Sa J Procedimiento de obtencion del acido 2-((3-3,4-dimetoxifenil-1-oxo-2-propenil)amino)benzoico
US5356620A (en) * 1989-04-04 1994-10-18 Kissei Pharmaceutical Co. Ltd. Pharmaceutical compositions containing N-(3,4-dimethoxycinnamoyl) anthranilic acid
JP2001187728A (ja) * 1999-12-28 2001-07-10 Lion Corp 眼科用組成物
JP2005247819A (ja) * 2003-09-30 2005-09-15 Rohto Pharmaceut Co Ltd 透明包装体入りトラニラスト含有医薬製剤
JP2006306765A (ja) * 2005-04-27 2006-11-09 Nippon Tenganyaku Kenkyusho:Kk トラニラスト水性点眼液
WO2010071865A1 (en) * 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
CN104379130A (zh) * 2012-03-30 2015-02-25 诺弗米克斯有限公司 曲尼司特组合物和共结晶体
KR20180078966A (ko) * 2016-12-30 2018-07-10 한국과학기술원 진동 감쇠 장치

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NA GENG ETAL: "Approach of Cocrystallization to Improve the Solubility and Photostability of Tranilast", 《CRYST. GROWTH DES.》 *
曹元华 等: "《中国女性皮肤病学》", 31 December 2009 *

Also Published As

Publication number Publication date
EP3837238B1 (en) 2024-06-12
EP3837238A1 (en) 2021-06-23
US20210155577A1 (en) 2021-05-27
WO2020035546A1 (en) 2020-02-20
JP2021533080A (ja) 2021-12-02
US12084399B2 (en) 2024-09-10
EP3837238C0 (en) 2024-06-12
JP7372259B2 (ja) 2023-10-31
US11078155B2 (en) 2021-08-03
US20210332003A1 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
US10150729B2 (en) Tranilast compositions and cocrystals
JP2023082086A (ja) キナーゼ阻害剤化合物の結晶多形、それを含む医薬組成物及びその製造方法と応用
US12084399B2 (en) Crystalline tranilast salts and their pharmaceutical use
TWI540131B (zh) 阿瑞吡坦(aprepitant)l-脯胺酸組成物及共晶體
JP7453475B2 (ja) オラパリブシュウ酸共結晶及びその医薬的使用
US11945814B2 (en) Salt form
CN118696032A (zh) 奥拉帕尼羟基苯甲酸共晶体及其药物用途
US8871793B2 (en) Metaxalone cocrystals
JP7597771B2 (ja) 治療のためのベンズアミド共結晶
HK40049105B (en) Crystalline tranilast salts and their pharmaceutical use
HK40049105A (en) Crystalline tranilast salts and their pharmaceutical use
HK1206619B (en) Tranilast compositions and cocrystals

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination